Why the study?
The study was conducted to prospectively evaluate the efficacy of tenapanor during its introduction phase in hemodialysis patients.
Does tenapanor reduce serum phosphorus levels in maintenance hemodialysis patients with secondary hyperparathyroidism?
Does tenapanor reduce serum phosphorus levels in maintenance hemodialysis patients with secondary hyperparathyroidism?
Tenapanor effectively reduces serum phosphorus levels in hemodialysis patients when added to existing phosphate binders, though diarrhea is a common adverse event leading to discontinuation in nearly a quarter of patients.
Answers are grounded in this paper and cite their sources.
Supports add-on tenapanor for phosphorus control in hemodialysis with secondary hyperparathyroidism; extends prior evidence despite 24% diarrhea discontinuation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Okazaki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: